AI Terminal
Fresenius Medical Care AG & Co. KGaA
Regulatory Filings • Dec 22, 2017
165_rns_2017-12-22_3e81459c-9eb1-425a-8645-0982100ecb6a.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 22 December 2017 21:20
Fresenius Medical Care AG & Co. KGaA expects material positive effects from US tax reform
Fresenius Medical Care AG & Co. KGaA / Key word(s): Final Results/Miscellaneous
Fresenius Medical Care AG & Co. KGaA expects material positive effects from US tax reform
22-Dec-2017 / 21:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, expects material positive effects from the tax reform legislation signed into law in the United States today. The new law goes into effect on January 1, 2018.
In particular, the new legislation triggers the re-evaluation of deferred tax liabilities. This results in a one-time book gain of around 200 million Euro, to be reflected in 2017 Earnings After Tax.
On February 27, 2018 the company will release its 2017 business results and discuss the ongoing tax effect as part of its guidance for 2018.
22-Dec-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Fresenius Medical Care AG & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | [email protected] |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE |
| End of Announcement | DGAP News Service |